Understanding Legal Options for Similac-Related Necrotizing Enterocolitis Claims

From General Health Information to Product Liability

For decades, general health and science information has served as a foundational resource for public understanding, offering broad guidance on nutrition, wellness, and medical awareness. This legacy context has helped individuals navigate everyday health decisions, from dietary choices to recognizing early signs of illness. Within this framework, infant nutrition has been a recurring topic, with emphasis on the benefits of breast milk and the role of formula as a safe alternative when needed. As public health awareness has evolved, so too has the scrutiny of specific products once considered routine. In the domain of mass production, the scale at which infant formulas are manufactured and distributed introduces unique considerations. When a widely used product becomes the subject of legal claims, the focus shifts from general nutritional advice to the specific circumstances of exposure and potential harm. The transition from broad health education to consumer exposure concern is marked by a growing need to understand legal pathways for those affected. This pivot requires examining how large-scale production and distribution can lead to unintended consequences, particularly when vulnerable populations—such as premature infants—are involved. The discussion now moves from general wellness principles to the concrete realities of product liability, where understanding legal options becomes paramount for those seeking accountability after exposure to a potentially harmful substance.

Find Out If You Qualify for Compensation →

The Medical Link Between Similac and Necrotizing Enterocolitis

Necrotizing enterocolitis (NEC) is a severe gastrointestinal disease primarily affecting preterm infants. The condition involves inflammation and necrosis of the intestinal tissue, which can progress to perforation, peritonitis, and systemic infection. Clinical presentation typically includes bloody stools, vomiting, and abdominal distension (https://pubmed.ncbi.nlm.nih.gov/37856666). Diagnosis is based on clinical signs, radiographic findings (e.g., pneumatosis intestinalis), and laboratory markers of infection and inflammation. NEC is a leading cause of morbidity and mortality in neonatal intensive care units, with outcomes including death, need for surgical resection, and long-term neurodevelopmental impairment. Similac is a brand of cow’s milk-based infant formula manufactured by Abbott Laboratories. The primary protein source in standard Similac products is cow’s milk protein, which includes casein and whey. In preterm infants, exposure to bovine-based milk proteins has been associated with an increased risk of developing cow’s milk protein allergy (CMPA) (https://pubmed.ncbi.nlm.nih.gov/37856666). CMPA in preterm infants shares many gastrointestinal symptoms with NEC, including bloody stools, vomiting, and abdominal distension (https://pubmed.ncbi.nlm.nih.gov/37856666). The literature indicates that preterm infants exposed to cow’s milk-based formula in their first days of life have a higher risk of developing CMPA (https://pubmed.ncbi.nlm.nih.gov/37856666). Additionally, food protein-induced allergic proctocolitis (FPIAP), a form of CMPA, is commonly seen in healthy, full-term infants who present with rectal bleeding and can occur in both formula-fed and exclusively breastfed infants (https://pubmed.ncbi.nlm.nih.gov/33262206). Preterm infants are susceptible to food allergy, as demonstrated from several case reports of NEC-like illnesses that responded clinically to cow’s milk elimination (https://pubmed.ncbi.nlm.nih.gov/33262206).

Mechanisms and Evidence Linking Similac to NEC

The mechanistic link between cow’s milk-based formula and NEC is not fully understood but is thought to involve immune-mediated and inflammatory pathways. Cow’s milk proteins can act as antigens, triggering an allergic response in susceptible preterm infants. This immune activation may lead to intestinal inflammation, mucosal damage, and impaired barrier function, predisposing the infant to bacterial translocation and NEC. Evidence from network meta-analyses suggests that mother’s own milk, with or without donor milk and human-milk-based fortifier, is associated with better outcomes for mortality, NEC, and time to reach full enteral feeds compared to bovine-based products (https://pubmed.ncbi.nlm.nih.gov/40431391). The top-ranked treatment class for reducing NEC was mother’s own milk with donor milk and a human-milk-based fortifier (https://pubmed.ncbi.nlm.nih.gov/40431391). This supports the hypothesis that avoidance of cow’s milk proteins may reduce NEC risk. Furthermore, lactoferrin supplementation, a component of human milk, has been shown to reduce late-onset sepsis but not NEC or all-cause mortality in preterm infants (https://pubmed.ncbi.nlm.nih.gov/32407710). The adequacy of warnings provided by Abbott Laboratories regarding the risk of NEC associated with Similac use in preterm infants is a central issue in legal claims. Current product labels for standard Similac formulas do not explicitly warn about the potential increased risk of NEC in preterm infants. The evidence indicates that preterm infants exposed to cow’s milk-based formula have a higher risk of developing CMPA, which can mimic or trigger NEC (https://pubmed.ncbi.nlm.nih.gov/37856666). Additionally, clinical guidelines strongly advocate that human milk with mothers on a cow’s milk-free diet is the first choice of feed after diagnosis of CMPA (https://pubmed.ncbi.nlm.nih.gov/37856666). The absence of a clear warning on Similac products about this risk may have led to continued use in vulnerable preterm populations without informed consent from parents or healthcare providers.

Settlement Considerations and Legal Options

Legal claims regarding Similac and NEC have been consolidated into multidistrict litigation (MDL) in the United States. Affected families may be eligible for compensation if they can demonstrate that their infant developed NEC after exposure to Similac and that the manufacturer failed to provide adequate warnings. Settlement considerations typically include the severity of the infant’s injury (e.g., need for surgery, length of hospital stay, long-term complications), the duration and exclusivity of formula feeding, and the presence of other risk factors such as prematurity and low birth weight. Evidence from the literature shows that outcomes for NEC include mortality, retinopathy of prematurity, sepsis, periventricular leukomalacia, bronchopulmonary dysplasia, and developmental scores (https://pubmed.ncbi.nlm.nih.gov/40431391). These outcomes can form the basis for calculating damages in settlement negotiations. The timeline between exposure to Similac and the development of NEC is variable but typically occurs within the first few weeks of life in preterm infants. The literature indicates that most preterm infants with CMPA were exposed to bovine-based milk proteins before the development of symptoms (https://pubmed.ncbi.nlm.nih.gov/37856666). In case reports, symptoms such as bloody stools, vomiting, and abdominal distension often appear within days to weeks of initiating cow’s milk-based formula. The diagnosis of NEC is usually confirmed radiographically or surgically within this period. The rapid onset of symptoms underscores the importance of early recognition and dietary modification, such as switching to human milk or extensively hydrolyzed formula.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is necrotizing enterocolitis (NEC) and how is it linked to Similac?

NEC is a severe gastrointestinal disease primarily affecting preterm infants, involving inflammation and necrosis of intestinal tissue. Studies have shown that preterm infants exposed to cow’s milk-based formula like Similac have a higher risk of developing cow’s milk protein allergy, which can mimic or trigger NEC (https://pubmed.ncbi.nlm.nih.gov/37856666).

What legal options are available for families affected by Similac-related NEC?

Legal claims regarding Similac and NEC have been consolidated into multidistrict litigation (MDL) in the United States. Families may be eligible for compensation if they can demonstrate that their infant developed NEC after Similac exposure and that the manufacturer failed to provide adequate warnings about the risk.

What evidence supports the link between Similac and NEC?

Evidence includes network meta-analyses showing that mother’s own milk is associated with better outcomes compared to bovine-based products (https://pubmed.ncbi.nlm.nih.gov/40431391), and studies indicating that preterm infants exposed to cow’s milk formula have a higher risk of CMPA (https://pubmed.ncbi.nlm.nih.gov/37856666).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented similac exposure and a confirmed Injury diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.